AUA: Flibanserin Shows Promise for Sexual Dysfunction in Females
MONDAY, May 15, 2017 -- Flibanserin (Addyi) may improve some measures of sexual dysfunction in premenopausal women, according to a study presented at the annual meeting of the American Urological Association, held from May 12 to 16 in Boston.
Researchers collected data on 2,360 premenopausal women who participated in three 24-week studies that compared flibanserin to an inactive placebo. All of the women had hypoactive sexual desire disorder. The response to the drug was measured using the Female Sexual Function Index.
The researchers found that, compared with a placebo, women taking a daily dose of flibanserin reported significant improvement in desire and the other areas of sexual function assessed by the index: arousal, lubrication, orgasm, satisfaction, and pain.
The drug is only approved by the U.S. Food and Drug Administration for premenopausal women, not postmenopausal women or men, according to a news release from the American Urological Association. The most common side effects are sleepiness and dizziness, but since the drug is taken before bedtime, these effects are usually not harmful. Other side effects include nausea, fatigue, insomnia, and dry mouth.
The research was funded by Valeant Pharmaceuticals North America, the maker of flibanserin.
© 2019 HealthDay. All rights reserved.
Posted: May 2017